Actively Recruiting
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-09-08
21
Participants Needed
1
Research Sites
118 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.
CONDITIONS
Official Title
Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older
- Histologically confirmed solitary bone plasmacytoma with less than 10% clonal plasma cells in bone marrow
- ECOG performance status of 2 or less
- No prior anti-myeloma therapy (previous local radiotherapy for SBP allowed)
- Meets required laboratory and imaging criteria
You will not qualify if you...
- Previous treatment with anti-plasma cell therapies such as melphalan, cyclophosphamide, proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific antibodies, or CAR-T therapy
- Any condition deemed by the investigator to make participation unsuitable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China, 300020
Actively Recruiting
Research Team
G
Gang An, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here